Apotex Inc. v. Canada (Health), 2017 FC 857 (Omeprazole*)

Justice Roy - 2017-09-25

Read full decision. Automatically generated summary:

In what is in the process of becoming a veritable saga concerning its Apo-Omeprazole Magnesium Tablets [or Apo-Omeprazole], the applicant is once again before this Court on a judicial review application, presumably pursuant to section 18.1 of the Federal Courts Act (RSC, 1985, c F-7). The relief sought is concerned with the decision of the Minister of Health [the Minister or the respondent] to cancel the reconsideration of Apotex’s submission concerning a Notice of Compliance [NOC] in respect of Apotex’s Apo-Omeprazole (omeprazole magnesium) Tablets and to treat its submission as withdrawn. That is the decision of the Minister of November 16, 2015, cancelling the reconsideration which the applicant wants squashed; the applicant also seeks that the Minister continue to process its submission without fettering her discretion “by insisting on strict compliance with policies and guidelines which do not have force of law”. The applicant seeks an alternative remedy:

Decision relates to:


Canadian Intellectual Property